Narrow use codes can also lead to failures by generic drug companies to carve-out critical label information.
January 03, 2022
Court reinstates $236 million verdict against Teva for marketing generic version of Coreg® as “AB rated”
October 18, 2020
Generic competition looms for Amarin’s Vascepa (“icosapent ethyl” or “EPA”) capsules in spite of 52 patents listed in FDA’s Orange Book.
June 16, 2020